Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
A 20-week RCT finds adding empagliflozin improves glucose, kidney function, neuropathy symptoms, and nerve conduction velocity in type 2 diabetes, though amplitude and exam scores were unchanged. PICO summary and commentary.
A 12-week RCT finds adding sitagliptin to metformin improves fasting glucose, lipids, beta-cell function, and inflammatory cytokines, though HbA1c did not change significantly. PICO summary and commentary.
A subgroup analysis finds adding Control-IQ+ automated insulin delivery to GLP-1 agonist therapy lowers HbA1c and improves time in range without weight gain in insulin-treated type 2 diabetes. PICO summary and commentary.
A single-blind RCT finds personalised exercise prescribed from the Chester Step Test reduces glycaemic variability in type 2 diabetes under free-living conditions. PICO summary and commentary.
A quasi-experimental Nigerian trial finds a print-based educational module with leaflets and reminders significantly improves diabetes self-care practices versus no intervention. PICO summary and commentary.
A six-arm trial finds combined training plus astaxanthin best improves oxidative and inflammatory markers in women with type 2 diabetes, but glycaemic gains come from exercise, not the supplement. PICO summary and commentary.
An RCT finds adding a ketogenic diet to dulaglutide improves glucose, lipids, insulin resistance, sleep, and quality of life more than dulaglutide alone in type 2 diabetes. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
